Amitriptyline-paroxetine

From Psychiatrienet
Revision as of 16:21, 6 August 2009 by Walter (talk | contribs)
Jump to: navigation, search
Amitriptyline
Type Antidepressant
Group TCA
links
ATC-code N06AA09
Medscape Amitriptyline
PubChem 2160
PubMed Amitriptyline
Kompas (Dutch) Amitriptyline
Wikipedia Amitriptyline
paroxetine
Type Antidepressant
Group SSRI
links
Medscape paroxetine
PubChem 43815
PubMed paroxetine
Kompas (Dutch) paroxetine
Wikipedia paroxetine

Switch medication from amitriptyline to paroxetine.[1] [2]

Nietinrijdenbord.png Stop amitriptyline
  • Before day 0: gradually reduce dosage of amitriptyline to a maximum of 50 mg/day.
  • Day 1: reduce dosage of amitriptyline to 25 mg/day.
  • Day 8: stop dosage of amitriptyline.
Eenrichtingbord.png Start paroxetine
  • Day 15: start administration of paroxetine in a normal dosage of 20 mg/day.
Infobord.png More information
  • Occurrence of the serotonin syndrome is not likely, but theoretically possible, so caution is necessary.
  • Paroxetine is a strong inhibitor of CYP2D6, which metabolizes amitriptyline.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.